CC 401

Drug Profile

CC 401

Alternative Names: CC-401; JNK-401

Latest Information Update: 01 Apr 2008

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Small molecules
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Inflammation

Most Recent Events

  • 31 Oct 2005 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)
  • 12 Nov 2003 Phase-I clinical trials in Inflammation in USA (IV)
  • 12 Nov 2003 Phase-I clinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top